ABCSG45 is a trial which we conducted in HR-positive triple-negative breast cancer patients. It’s a trial that was set in the neoadjuvant setting. The primary endpoint was the residual cancer burden score. So the idea was to offer a new kind of combination between carboplatin and a PARP inhibitor named olaparib, and we were wondering whether the RCB0 rate, which is the complete or the almost complete pathological remission, would actually increase...
ABCSG45 is a trial which we conducted in HR-positive triple-negative breast cancer patients. It’s a trial that was set in the neoadjuvant setting. The primary endpoint was the residual cancer burden score. So the idea was to offer a new kind of combination between carboplatin and a PARP inhibitor named olaparib, and we were wondering whether the RCB0 rate, which is the complete or the almost complete pathological remission, would actually increase. We did see that this was the case for patients with a BRCA-mutated tumor, but in patients without BRCA-mutated tumors, the efficacy of Olaparib-carboplatin combinations were lower.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
